<?xml version='1.0' encoding='utf-8'?>
<document id="19370547"><sentence text="Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation."><entity charOffset="121-130" id="DDI-PubMed.19370547.s1.e0" text="methadone" /><entity charOffset="132-145" id="DDI-PubMed.19370547.s1.e1" text="buprenorphine" /><entity charOffset="151-164" id="DDI-PubMed.19370547.s1.e2" text="diprenorphine" /><pair ddi="false" e1="DDI-PubMed.19370547.s1.e0" e2="DDI-PubMed.19370547.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19370547.s1.e0" e2="DDI-PubMed.19370547.s1.e1" /><pair ddi="false" e1="DDI-PubMed.19370547.s1.e0" e2="DDI-PubMed.19370547.s1.e2" /><pair ddi="false" e1="DDI-PubMed.19370547.s1.e1" e2="DDI-PubMed.19370547.s1.e1" /><pair ddi="false" e1="DDI-PubMed.19370547.s1.e1" e2="DDI-PubMed.19370547.s1.e2" /></sentence><sentence text="Conclusions based on either in vitro or in vivo approach to evaluate the P-gp affinity status of opioids may be misleading" /><sentence text=" For example, in vitro studies indicated that fentanyl is a P-gp inhibitor while in vivo studies indicated that it is a P-gp substrate"><entity charOffset="46-54" id="DDI-PubMed.19370547.s3.e0" text="fentanyl" /></sentence><sentence text=" Quite the opposite was evident for meperidine"><entity charOffset="36-46" id="DDI-PubMed.19370547.s4.e0" text="meperidine" /></sentence><sentence text=" The objective of this study was to evaluate the P-gp affinity status of methadone, buprenorphine and diprenorphine to predict P-gp-mediated drug-drug interactions and to determine a better candidate for management of opioid dependence"><entity charOffset="73-82" id="DDI-PubMed.19370547.s5.e0" text="methadone" /><entity charOffset="84-97" id="DDI-PubMed.19370547.s5.e1" text="buprenorphine" /><entity charOffset="102-115" id="DDI-PubMed.19370547.s5.e2" text="diprenorphine" /><pair ddi="false" e1="DDI-PubMed.19370547.s5.e0" e2="DDI-PubMed.19370547.s5.e0" /><pair ddi="false" e1="DDI-PubMed.19370547.s5.e0" e2="DDI-PubMed.19370547.s5.e1" /><pair ddi="false" e1="DDI-PubMed.19370547.s5.e0" e2="DDI-PubMed.19370547.s5.e2" /><pair ddi="false" e1="DDI-PubMed.19370547.s5.e1" e2="DDI-PubMed.19370547.s5.e1" /><pair ddi="false" e1="DDI-PubMed.19370547.s5.e1" e2="DDI-PubMed.19370547.s5.e2" /></sentence><sentence text=" Two in vitro (P-gp ATPase and monolayer efflux) assays and two in vivo (tissue distribution and antinociceptive evaluation in mdr1a/b (-/-) mice) assays were used" /><sentence text=" Methadone stimulated the P-gp ATPase activity only at higher concentrations, while verapamil and GF120918 inhibited its efflux (p &lt; 0"><entity charOffset="1-10" id="DDI-PubMed.19370547.s7.e0" text="Methadone" /></sentence><sentence text="05)" /><sentence text=" The brain distribution and antinociceptive activity of methadone were enhanced (p &lt; 0"><entity charOffset="56-65" id="DDI-PubMed.19370547.s9.e0" text="methadone" /></sentence><sentence text="05) in P-gp knockout mice" /><sentence text=" Conversely, buprenorphine and diprenorphine were negative in all assays"><entity charOffset="13-26" id="DDI-PubMed.19370547.s11.e0" text="buprenorphine" /><entity charOffset="31-44" id="DDI-PubMed.19370547.s11.e1" text="diprenorphine" /><pair ddi="false" e1="DDI-PubMed.19370547.s11.e0" e2="DDI-PubMed.19370547.s11.e0" /><pair ddi="false" e1="DDI-PubMed.19370547.s11.e0" e2="DDI-PubMed.19370547.s11.e1" /></sentence><sentence text=" P-gp can affect the PK/PD of methadone, but not buprenorphine or diprenorphine"><entity charOffset="30-39" id="DDI-PubMed.19370547.s12.e0" text="methadone" /><entity charOffset="49-62" id="DDI-PubMed.19370547.s12.e1" text="buprenorphine" /><entity charOffset="66-79" id="DDI-PubMed.19370547.s12.e2" text="diprenorphine" /><pair ddi="false" e1="DDI-PubMed.19370547.s12.e0" e2="DDI-PubMed.19370547.s12.e0" /><pair ddi="false" e1="DDI-PubMed.19370547.s12.e0" e2="DDI-PubMed.19370547.s12.e1" /><pair ddi="false" e1="DDI-PubMed.19370547.s12.e0" e2="DDI-PubMed.19370547.s12.e2" /><pair ddi="false" e1="DDI-PubMed.19370547.s12.e1" e2="DDI-PubMed.19370547.s12.e1" /><pair ddi="false" e1="DDI-PubMed.19370547.s12.e1" e2="DDI-PubMed.19370547.s12.e2" /></sentence><sentence text=" Our report is in favor of buprenorphine over methadone for management of opioid dependence"><entity charOffset="27-40" id="DDI-PubMed.19370547.s13.e0" text="buprenorphine" /><entity charOffset="46-55" id="DDI-PubMed.19370547.s13.e1" text="methadone" /><entity charOffset="74-80" id="DDI-PubMed.19370547.s13.e2" text="opioid" /><pair ddi="false" e1="DDI-PubMed.19370547.s13.e0" e2="DDI-PubMed.19370547.s13.e0" /><pair ddi="false" e1="DDI-PubMed.19370547.s13.e0" e2="DDI-PubMed.19370547.s13.e1" /><pair ddi="false" e1="DDI-PubMed.19370547.s13.e0" e2="DDI-PubMed.19370547.s13.e2" /><pair ddi="false" e1="DDI-PubMed.19370547.s13.e1" e2="DDI-PubMed.19370547.s13.e1" /><pair ddi="false" e1="DDI-PubMed.19370547.s13.e1" e2="DDI-PubMed.19370547.s13.e2" /></sentence><sentence text=" Buprenorphine most likely is not a P-gp substrate and concerns regarding P-gp-mediated drug-drug interaction are not expected"><entity charOffset="1-14" id="DDI-PubMed.19370547.s14.e0" text="Buprenorphine" /></sentence><sentence text="" /></document>